GENETIC TECHNOLOGIES LTD
NASDAQ: GENE (Genetic Technologies Ltd)
Kemas kini terakhir: semalam, 11:22AM0.000
0.00 (0.00%)
| Harga / Jualan (P/S) | 0.560 |
| Harga / Buku (P/B) | 3.29 |
| Margin Keuntungan | -124.24% |
| Margin Operasi (TTM) | -113.14% |
| EPS Cair (TTM) | -0.020 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | -10.60% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 47.81% |
| Nisbah Semasa (MRQ) | 0.880 |
| Aliran Tunai Operasi (OCF TTM) | -9.68 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -5.72 M |
| Pulangan Atas Aset (ROA TTM) | -62.93% |
| Pulangan Atas Ekuiti (ROE TTM) | -184.98% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Diagnostics & Research (US) | Menaik | Bercampur |
| Diagnostics & Research (Global) | Menaik | Bercampur | |
| Stok | Genetic Technologies Ltd | - | - |
AISkor Stockmoo
| Konsensus Penganalisis | 2.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | 3.0 |
| Purata Bergerak Teknikal | -2.5 |
| Osilator Teknikal | 0.0 |
| Purata | 0.63 |
|
Genetic Technologies Ltd is an Australia-based molecular diagnostics company that offers predictive testing and assessment tools to help physicians proactively manage women's health. The company has developed BREVAGenplus which is a clinically validated risk assessment test for non-hereditary breast cancer. It also provides genetic testing services including medical testing, animal testing, forensic testing, and plant testing. The company markets BREVAGenplus to healthcare professionals in breast healthcare and imaging centers, as well as to obstetricians/ gynecologists (OBGYNs) and breast cancer risk assessment specialists. The majority of the company's revenue is generated from Australia and the United States. The group has two operating segments: EasyDNA and GeneType/Corporate. |
|
| Sektor | Healthcare |
| Industri | Diagnostics & Research |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Institusi | 1.87% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Ashton Thomas Securities, Llc | 30 Sep 2024 | 5 |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |